Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Radiotherapy
Clinical trial register · China

Radiotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 21 Beijing 14 Shanghai 11 Jinan 8 Wuhan 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University8 Sun Yat-sen University8 Fudan University7 Shandong Cancer Hospital and Institute4 Cancer Institute and Hospital, Chinese Academy of Medical Sciences4
Site location
Guangzhou21 Beijing14 Shanghai11 Jinan8 Wuhan6
All 43 locations
Target enrolment
to

Radiotherapy trials in China

77 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
zhaoxiaohui
Not applicable
62
Guangzhou
2026-11-09
Not yet open
Tao Zhang
Phase 2
144
Wuhan
2026-11-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
73
Beijing
2026-10-08
Not yet open
Ke Hu
Phase 2
46
Beijing
2026-09-10
Recruiting
Shandong Cancer Hospital and Institute
Phase 3
180
Jinan
2026-08-15
Recruiting
Jiangmen Central Hospital
Phase 2
43
Jiangmen
2026-07-20
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
23
Guangzhou
2026-07-01
Not yet open
Sichuan University
Observational
200
Chengdu
2026-06-30
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
122
Nanjing
2026-05-20
Recruiting
Tao Zhang
Phase 3
444
Wuhan
2026-05-15
Recruiting
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
NCT07565532Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment
Shanghai Chest Hospital
Observational
500
Shanghai
2026-04-01
Recruiting
Tao Zhang
Phase 2
25
Wuhan
2026-01-01
Recruiting
Association Between Clinical Classification and Prognosis in Chronic Radiation Enteropathy
NCT07378631Radiotherapy, Radiation Proctitis, Radiation Enteritis
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Guangzhou
2025-12-04
Recruiting
PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
NCT07267234Solid Cancer, Lymphopenia, Radiotherapy, Immune Checkpoint Inhibitor
Second Affiliated Hospital of Soochow University
Phase 2
65
Suzhou
2025-12-01
Recruiting
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
NCT07742332EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy
Peng Zhang
Phase 2
160
Shanghai
2025-11-25
Recruiting
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2025-10-15
Recruiting
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
NCT07071103Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
Chuangzhen Chen
Phase 2
48
Shantou
2025-09-26
Not yet open
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07196345ESCC, TAS 102, Radiotherapy
DrugTrifluridine/Tipiracil
Qianfoshan Hospital
Phase 1/2
45
Jinan
2025-09-25
Not yet open
Sun Yat-sen University
Not applicable
58
Guangzhou
2025-09-15
Recruiting
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
NCT07284992Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
Shandong Provincial Hospital
Phase 2
208
Jinan
2025-09-12
Recruiting
The Effect of Radiotherapy After Separation Surgery for Spinal Metastases
NCT07527884Spinal Metastases, Spinal Tumor, Radiotherapy, Separation Surgery
Wei Xu
Not applicable
130
Shanghai
2025-09-01
By invitation
Fudan University
Observational
128
Shanghai
2025-09-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
52
Guangzhou
2025-08-30
Recruiting
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
50
Guangzhou
2025-08-01
Recruiting
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
NCT07062055Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
DrugAnti-VEGF
Shandong Cancer Hospital and Institute
Phase 2
54
Jinan
2025-07-25
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
NCT06841172OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Shandong Cancer Hospital and Institute
Phase 3
132
Jinan
2025-07-21
Not yet open
Nanfang Hospital, Southern Medical University
Observational
338
Guangzhou, Huizhou, Meizhou
2025-07-20
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Not yet open
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
176
Guangzhou
2025-05-31
Recruiting
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
NCT06958432Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3
430
Guangzhou
2025-05-06
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3
286
Guangzhou
2025-05-01
Recruiting
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
NCT06923345Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
80
Guangzhou
2025-03-31
Recruiting
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
452
Shanghai
2025-02-01
Recruiting
Dietary Supplements to Treat Radiation-Induced Rectal Injury
NCT06776016Radiotherapy, Radiation Proctitis
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
33
Guangzhou
2025-01-15
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Active, closed
RT for Adenocarcinoma/Adenosquamous Carcinoma
NCT07153952Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy
Peking Union Medical College Hospital
Phase 1/2
60
Beijing
2025-01-01
Not yet open
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
NCT06708650Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
Guiping People's Hospital
Not applicable
50
Guiping
2025-01-01
Recruiting
Peking University Cancer Hospital & Institute
Observational
500
Beijing, Hohhot, Kunming
2024-12-01
Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
West China Hospital
Phase 3
184
Chengdu
2024-11-19
Recruiting
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
NCT06676449Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
432
Shanghai
2024-11-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Recruiting
Guangdong Provincial People's Hospital
Phase 4
39
Guangzhou
2024-08-10
Recruiting
Spectral CT in Radiotherapy for Cervical Cancer
NCT06433817Cervical Cancer, Radiotherapy
Peking Union Medical College Hospital
Observational
150
Beijing
2024-05-22
Recruiting
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
DrugPembrolizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-05-01
Recruiting
Fudan University
Phase 2
30
Shanghai
2024-04-01
Recruiting
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-03-13
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
DrugCadonilimab
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Not yet open
MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
NCT06197126Cervical Cancer, Radiotherapy, Prognostic Model, MRI
Fujian Cancer Hospital
Observational
200
Fuzhou
2024-01-01
Recruiting
Feng Tian
Phase 2
31
Jinan
2024-01-01
Recruiting
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
NCT06255223Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
Jinling Hospital, China
Phase 2
35
Nanjing
2023-12-15
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
DrugsJS001·Toripalimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
64
Guangzhou
2023-12-01
Not yet open
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
NCT06101966Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
Fujian Cancer Hospital
Observational
500
Fuzhou
2023-12-01
By invitation
Xiaomeng Zheng
Observational
40
Fuzhou
2023-11-29
Recruiting
Ming-Yuan Chen
Not applicable
86
Guangzhou, Zhuhai
2023-11-01
Recruiting
Xinqiao Hospital of Chongqing
Not applicable
40
Chongqing
2023-08-01
Recruiting
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
NCT06120426Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
Shanghai Changzheng Hospital
Observational
182
Shanghai
2023-07-01
Recruiting
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
324
Guangzhou
2023-01-01
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Not yet open
Chinese Academy of Medical Sciences
Phase 2/3
588
Beijing, Shenzhen
2022-08-06
Recruiting
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
NCT05349552Radiotherapy, Thoracic Cancer, Safety and Efficacy
Peking University Third Hospital
Observational
120
Beijing
2022-05-01
Active, closed
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
NCT05176002Esophageal Neoplasm, Immunotherapy, Radiotherapy
DrugCamrelizumab
Fujian Medical University Union Hospital
Phase 1/2
25
Fuzhou
2021-11-10
Not yet open
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
NCT04956601Endometrial Cancer, Pathology, Radiotherapy
Peking University Third Hospital
Not applicable
480
Beijing
2021-07
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
DrugCamrelizumab
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Recruiting
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
DrugToripalimab
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Active, closed
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
NCT04384627Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
Sun Yat-sen University
Phase 3
445
Foshan, Zhongshan
2019-12-01
Recruiting
Fudan University
Observational
500,000
Shanghai
2008-01-01
Rows per page Showing 1–77 of 77
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/radiotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 77 of those studies listing the condition Radiotherapy.

How many Radiotherapy trials are recruiting in China?

57 of the 77 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 14 have not yet opened recruitment, 4 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Radiotherapy), 77 studies
PhaseStudiesRecruitingShare
Phase 2302539%
Observational14818.2%
Phase 3141318.2%
Not applicable12815.6%
Phase 1/2303.9%
Phase 2/3323.9%
Phase 4111.3%

Most active sponsors

Lead sponsors with the most studies (Radiotherapy)
Lead sponsorStudiesRecruiting
Sixth Affiliated Hospital, Sun Yat-sen University87
Sun Yat-sen University85
Fudan University76
Cancer Institute and Hospital, Chinese Academy of Medical Sciences44
Shandong Cancer Hospital and Institute44
Peking Union Medical College Hospital32
Tao Zhang32
Fujian Cancer Hospital20
Hubei Cancer Hospital22
Nanfang Hospital, Southern Medical University21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.